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A New Scoring System to Determine Thromboembolic Risk
After Heart Valve Replacement
Eric G. Butchart, FRCS, FETCS, FESC; Adrian Ionescu, MRCP (UK); Nicola Payne, MPhil;
John Giddings, PhD, FRCPath, FIBMS; Gary L. Grunkemeier, PhD; Alan G. Fraser, FRCP, FESC
Objective—To determine the most important inflammatory and hematologic predictors of thromboembolism (TE) in
patients undergoing valve replacement (VR) to be used in conjunction with clinical risk factors for preoperative risk
profiling.
Methods and Results—Preoperative and immediately postoperative clinical, echocardiographic, hematologic, biochemical
and microbiological parameters were examined prospectively in 370 patients undergoing VR (249 AVR, 93 MVR, 28
DVR). Mean follow-up was 4.4 years (max 6.6 years; total 1566 pt/yrs), and 96 TE events were documented (28 major
and 68 minor). INR data were collected on all patients. Laboratory values were considered elevated if they exceeded
the 80th percentile of those of 70 controls with the same distribution of age and gender. IgA antibody to Chlamydia
pneumoniae (CP)1:64 was considered indicative of significant infection. Predictors of TE on multivariate analysis
following AVR were (hazard ratios): CP infection (2.6), previous TE (2.5), raised eosinophils (2.4), cancer history (2.1),
postoperative infection (2.0), hypertension (2.0), CABG  3/4 (2.0), and diabetes (1.9). Predictors of TE following
MVR/DVR were raised mean platelet volume (4.0), raised factor VII (3.1), CP infection (2.7), previous mitral
valvotomy (2.5), raised fibrinogen (2.2), and raised reticulocytes (2.0). These risk factors were additive when present
in the same patient, enabling a scoring system to be developed that accurately predicted risk of TE based on number
of risk factors.
Conclusions—Selected blood tests and clinical risk factors provide a scoring system that accurately predicts TE risk and
may guide prosthesis choice and antithrombotic management. (Circulation. 2003;108[suppl II]:II-68-II-74.)
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Thromboembolism and serious bleeding events togetheraccount for about 75% of the events reported as compli-
cations after mechanical valve replacement.1 The guidelines
for reporting these events recommend that all such events
should be attributed to the prosthesis,2 even though many are
almost certainly not prosthesis-related and simply part of the
background incidence of stroke, TIA and major bleeding in
the general population.3 This has led to the publication of
comparisons of one prosthesis versus another based on
thromboembolic (TE) rates in particular and has led some
manufacturers to claim in their advertising material that their
prosthesis has a lower TE rate than their competitors’
products. Yet examination of large numbers of published
series shows that there is as much variation in TE rates
between different series of the same type of prosthesis as
there is between one prosthesis and another.4
Three major factors are likely to account for these
differences in TE rates with the same type of prosthesis:
the method of data collection, the antithrombotic manage-
ment and the effect of patient risk factors. It has been
shown for example that different methods of collecting
data in the same cohort of patients yield TE rates that differ
by a factor of greater than 2;5 patients submitted to
questionnaire at the end of a long period of follow-up tend
to forget many minor events and this type of analysis
therefore always underestimates event rates. Different
intensity of anticoagulation also yields different TE rates
for the same prosthesis, particularly in the mitral position.6
The greatest influence on TE rates, however, probably
comes from individual patient factors and in particular
factors that increase stroke risk.3 It is self-evident that
patients suffer TE events, not prostheses, and to speak of
a prosthesis having a ‘TE rate’ makes no sense. Nor is it
meaningful to attempt meta-analyses on published series,
which differ widely in their methods of data collection and
in their patient populations, for the purposes of either
comparing one prosthesis with another or comparing one
antithrombotic regime with another.
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In an attempt to unravel the complex interplay of factors
responsible for thromboembolism after valve replacement, a
prospective study was initiated in 1995 with the aim of
identifying pre-operative clinical and laboratory variables
that would identify patients at risk of thromboembolism
during follow-up.
Methods
Selection of Patients
All patients undergoing elective valve replacement between June
1995 and July 1998 were eligible. Exclusion criteria were previous
valve replacement, valve replacement for complications of infective
endocarditis, emergency operations, and concomitant aortic root
replacement. The Local Research Ethics Committee approved the
protocol, and all patients gave informed consent. We recruited 370
patients (199 female), with a mean age (SD) of 669 years, who
underwent 249 aortic (AVR), 93 mitral (MVR), and 28 double
(aortic and mitral—DVR) valve replacement operations. The valves
used were bileaflet (St. Jude Standard—70 AVR, 35 MVR, 11 DVR,
and St. Jude Silzone—32 AVR, 13 MVR, 6 DVR), or single tilting
disc (Medtronic Hall—68 AVR, 27 MVR, 10 DVR, and Ultra-
cor—34 AVR, 18 MVR, 1 DVR) mechanical valves, or bioprosthe-
ses (Carpentier Edwards porcine or pericardial valves—45 AVR). A
comparison of the St. Jude Standard and St. Jude Silzone valves used
in this study, in terms of incidence of embolism and paravalvular
leak, will be reported separately.
Clinical and Laboratory Data
Medical history and current status were documented on admission by
interview and by examining the patients and their medical records.
Venous blood obtained a few days before the operation was tested
for hematologic, biochemical, and microbiological abnormalities.
IgA antibodies against Chlamydia pneumoniae (CP) were assayed
using a commercial indirect immunofluorescence method (MRL
Diagnostics). A titer of 1 in 64 was considered indicative of
significant infection. Routine blood counts, including hemoglobin
measurements, white cell differential counts, platelet parameters, and
reticulocyte counts were estimated using Advia 120 hematology
analysers (Bayer). Hemostasis assays were performed on blood
collected with minimum venous stasis using 21 gauge needles and
evacuated blood collection tubes containing 0.1vol 108 mmol/L
sodium citrate (Becton Dickenson). Platelet poor plasma was ob-
tained after centrifugation at 2000  g for 15 minutes at 4°C. The
thrombin time (TT), prothrombin time (PT), activated partial throm-
boplastin time (aPTT), factor VII (FVII), factor VIII (FVIII), and
fibrinogen assays (Clauss technique) were performed using standard
laboratory procedures.7,8 Von Willebrand factor antigen (vWFAg)
was measured by enzyme-linked immunoassay (ELISA) as described
by Giddings9 using commercially available antisera (Dako Ltd, UK).
Other investigations performed were transesophageal echocardi-
ography (TEE), carotid Doppler and transcranial Doppler (TCD) to
document high intensity transient signals (HITS).
Control Subjects
Healthy age- and sex-matched control subjects were recruited among
patients undergoing minor outpatient surgical procedures or attend-
ing an ophthalmology outpatient clinic, who had no history of
cardiovascular disease, no long-term medications, and a normal
physical examination. Current smokers were excluded. Control
subjects had the same blood tests as patients.
Follow-Up
Patients attended the outpatient clinic at 6 weeks and between 6 and
12 months after their operation for clinical examination and a
structured interview. The following events were documented: ische-
mic stroke, reversible ischemic neurological deficit (RIND), tran-
sient ischemic attack (TIA), and peripheral embolism. Ischemic or
hemorrhagic stroke was diagnosed with imaging studies at the time
of neurological events leading to hospital admission. International
normalized ratio (INR) levels were documented from patient-held
charts. Adequacy of anticoagulation was estimated by the percentage
of INRs within the target range (2.5 to 3.5). Beyond 1 year, patients
had annual interviews to document embolism and other end-points
until final follow-up in February 2002. Additional information was
obtained from patient charts. Copies of death certificates were
obtained from the UK Office of National Statistics.
Statistical Methods
Continuous data were described by mean (SD) and compared by
analysis of variance. Categorical data were described by percentages
and compared by Chi-square tests. Hematologic or biochemical data
were considered elevated if the value was greater than the 80th
percentile of normal, as determined from 70 control patients.
Univariate and multivariate Cox regression analyses were performed
to identify factors that were significantly associated with an in-
creased risk of TE events.10 The total number of multivariate risk
factors present in a single patient determined that patient’s ‘risk
score’. True hazard ratios from the Cox regression vary for patients
in the same count-group, depending on which particular set of risk
factors they have, but for simplification, counts rather than hazard
ratios were used to develop this risk score. Event free curves were
constructed using the actuarial method of Kaplan-Meier (KM).11
Statistical analysis was performed using SPSS for Windows, version
10.0.7 (SPSS, Chicago, IL) and the SPLUS software package,
version 2000 (Insightful, Inc, Seattle, WA).
Results
Baseline characteristics and hematology at entry into the
study are given for the whole group (Tables 1 and 2) and by
valve position (Tables 3 and 4). There were 70 controls (33
F), with a mean age (SD) of 63;11 they had none of the risk
factors described in Table 1, with the exception of previous
smoking (3% had stopped within the last 5 years and 34% had
stopped more than 5 years previously).
During follow-up for 0 to 6.6 years (mean 4.4, SD 1.6, total
follow-up 1567 patient-years, completeness of follow-up
TABLE 1. Baseline Characteristics
Patient Demographics
No Events
(n285)
Events
(n75)
Univariate
HR P
AGE 66.29.6 64.18.8 0.9 0.17
Female sex 52 60 1.3 0.26
Mitral or double valve 31 41 1.6 0.04
Current smoking 11 12 1.1 0.75
Systemic hypertension 22 29 1.3 0.20
Diabetes 6 12 2.3 0.02
Previous TE event 10 19 2.1 0.01
Non sinus rhythm 34 36 1.2 0.39
NYHA class 3 or 4 61 64 1.3 0.25
Cancer history 4 8 2.0 0.09
Previous mitral valvotomy 5 8 2.1 0.09
Previous MI 6 8 1.4 0.42
CAD at angiography 41 49 1.4 0.14
3 or 4 CABG 5 9 1.8 0.14
Postoperative infection 4 9 1.9 0.10
MeanSD, or (%). Abbreviations: CABG, coronary artery bypass grafts; CAD,
coronary artery disease; HR, hazard ratio on univariate analysis; MI, myocardial
infarction; NYHA, New York Heart Association; TE, thromboembolic.
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97.3%), 96 thromboembolic events occurred: 28 were major
(25 strokes and 3 peripheral emboli), and 68 minor (67
transient ischemic attacks and one reversible ischemic neu-
rologic deficit).
On univariate analysis, clinical and hematologic factors
significantly associated with TE, in order of their hazard
ratios, were: IgA antibodies to Chlamydia pneumoniae
(CP)1 in 64, factor VII90 iu/dL despite warfarin, diabe-
tes, previous event, previous valvotomy, cancer history,
reticulocyte count 86109/L, eosinophils 0.23109/L,
mean platelet volume 9.2fL, fibrinogen 3.5 g/L, and
mitral position. There was also a strong trend for an associ-
ation with postoperative infection, 3 or 4 CABG grafts, CAD
at angiography, lymphocytes 2.4109/L, and factor VIII
iu/dL 190 (Tables 1 and 2). Established stroke risk factors
(diabetes, previous event, and hypertension) were signifi-
cantly associated with an increase risk of TE events in
patients with aortic valve disease but not mitral or double
valve disease (Table 3), whereas elevations in hematologic
factors including mean platelet volume, factor VII, factor
VIII, and fibrinogen were more associated with events in
patients with mitral or double valve disease (Table 4).
On multivariate analysis, factors significantly associated
with TE in AVR patients were (hazard ratios): IgA antibodies
against CP1 in 64 (2.6), previous TE event (2.5), elevated
eosinophils (2.4), cancer history (2.1), postoperative infection
(2.0), hypertension (2.0), 3 or 4 CABG grafts (2.0), and
diabetes (1.9). For MVR/DVR patients, IgA antibodies
against CP1 in 64 (2.7), previous mitral valvotomy (2.5),
and elevations in mean platelet volume (4.0), factor VII
despite warfarin (3.1), fibrinogen (2.2), and reticulocytes
(2.0) were associated with an increased risk of TE.
Patients risk scores, which were calculated as the total
number of multivariate risk factors (as listed in Table 5),
ranged from 0 to 8 in this study. Freedom from all TE and
from major TE (ischemic stroke or peripheral embolism) by
risk score are shown in Figures 1 and 2, respectively. A score
of 0 to 6 risk factors effectively stratified patients and
permitted estimates of long-term TE risk to be created both in
terms of freedom from TE at 4 years and linearized rates
(Table 6).
Factors assessed as possible risk factors in this analysis,
which subsequently had no association with TE events,
included echocardiographic measurements (aortic atheroma
score, left atrial size, left ventricular dysfunction including
regional wall motion abnormalities), previous myocardial
infarction, internal carotid artery stenosis 60%, postopera-
tive HITS count, percentage of INR values outside the target
range, platelet aggregability, abnormalities of fibrinolytic
function, and abnormalities of lipid and homocysteine metab-
TABLE 3. Baseline Characteristics by Valve Position
Events in Patients with AVR Events in Patients with MVR
No Yes HR P No Yes HR P
n 197 44 88 31
AGE 6610 668 1.0 0.72 668 619 0.9 0.01
Female sex 44 48 1.1 0.67 72 77 1.2 0.65
Current smoking 11 11 1.1 0.92 9 13 1.3 0.64
Systemic hypertension 26 41 1.8 0.07 13 13 1.0 0.95
Diabetes 7 18 3.0 0.01 5 3 1.3 0.81
Previous TE event 7 21 2.8 0.01 16 16 1.3 0.56
Non sinus rhythm 13 5 0.4 0.20 81 81 1.2 0.76
NYHA class 3 or 4 55 50 1.0 0.95 76 84 1.7 0.26
Cancer history 4 9 2.3 0.11 3 7 1.7 0.46
Previous mitral valvotomy 1 0 0.05 0.95 13 19 2.0 0.13
Previous MI 7 7 1.2 0.76 3 10 1.7 0.38
CAD at angiography 45 57 1.7 0.08 33 39 1.2 0.65
3 or 4 CABG 6 9 2.0 0.19 5 10 1.4 0.59
Postoperative infection 5 14 2.7 0.03 3 3 0.9 0.91
MeanSD, or (%). Abbreviations: AVR, aortic valve replacement; CABG, coronary artery bypass
grafts; CAD, coronary artery disease; HR, hazard ratio on univariate analysis; MI, myocardial
infarction; MVR, mitral or double valve replacement; NYHA, New York Heart Association; TE,
thromboembolic.
TABLE 2. Laboratory Values
No Events
(n285)
Events
(n75)
Univariate
HR P
IgA antibodies to CP1:64 (%) 14 35 2.9 0.001
FVII despite warfarin (%) 5 15 2.5 0.01
Reticulocytes (%) 14 23 2.0 0.02
Eosinophils (%) 11 21 1.9 0.03
Mean platelet volume (%) 38 51 1.7 0.03
Fibrinogen (%) 35 45 1.6 0.04
Lymphocytes (%) 7 14 1.6 0.17
Factor VIII (%) 16 21 1.4 0.20
Data show the percentage of patients with an elevated level. Abbreviations:
CP, chlamydia pneumoniae; FVII, factor 7; HR, hazard ratio on univariate
analysis.
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olism. Genetic abnormalities of coagulation (factor V Leiden
and prothrombin) and homocysteine metabolism (MTHFR)
were also not predictive. On univariate analysis there was a
trend for an increased number of TE events in patients who
received a mechanical valve (n325) compared with those
who received a tissue valve (n45). However, on multivar-
iate analysis, this factor was displaced by other variables in
the model.
Discussion
This is the first study that has attempted to stratify the risk of
TE events after valve replacement based on a detailed
analysis of pre- and peri-operative variables. The addition of
a large number of laboratory variables to the more widely
acknowledged clinical variables in the analysis has enabled
many new factors to be identified that are related to an
increased risk of subsequent thromboembolism. These factors
appear to be additive in terms of risk prediction when they
occur in combination.
Among the clinical factors identified on multivariate anal-
ysis, 3 have not been described before; a past history of
cancer, previous closed mitral valvotomy, and postoperative
infection. Malignant disease in general and many individual
cancers in particular have been shown to be associated with
an increased risk of thrombosis through several different
prothrombotic mechanisms,12 but it is widely assumed that
the risk of thrombosis returns to ‘normal’ following effective
treatment of the cancer. The results of this study, with a 2-fold
increased risk of TE events, suggest that this is not the case,
as none of the patients in the study were known to have
residual or recurrent malignant disease at the time of surgery.
The explanation may be that prothrombotic abnormalities
persist even after effective cancer treatment or that these
abnormalities are long-standing and predate the cancer also,
as it is known that coagulation abnormalities are involved in
tumor cell growth and metastasis and may be related to
long-term prognosis.12,13 A raised eosinophil count some-
times occurs in occult14 and overt cancer15 and may be
TABLE 5. Variables Used in the Risk Score
for Thromboembolism
Previous TE event
Hypertension
Diabetes
3 or 4 CABG grafts
Cancer history
Postoperative infection
Previous mitral valvotomy
IgA antibodies against CP1 in 64
Mean platelet volume 9.2 fL
Eosinophils 0.23109/L
Factor VII despite warfarin 90 iu/dL
Fibrinogen 3.5 g/L
Reticulocytes 86109/L
Abbreviations: CABG, coronary artery bypass grafts.
TABLE 4. Laboratory Values by Valve Position
Events in Patients with AVR Events in Patients with MVR
No Yes HR P No Yes HR P
n 197 44 88 31
IgA to CP1:64 (%) 15 37 2.9 0.01 14 32 3.2 0.01
FVII despite warfarin (%) 3 2 1.0 0.97 10 32 2.5 0.02
Reticulocytes (%) 12 20 1.9 0.10 18 28 2.1 0.10
Eosinophils (%) 11 30 2.9 0.01 12 7 0.8 0.69
Mean platelet volume (%) 38 39 1.1 0.83 38 68 3.1 0.01
Fibrinogen (%) 35 41 1.4 0.31 38 52 1.9 0.10
Lymphocytes (%) 7 14 1.7 0.28 8 14 1.5 0.49
Factor VIII (%) 15 16 1.0 0.96 18 29 1.9 0.09
Data show the percentage of patients with an elevated level. Abbreviations: AVR, aortic valve
replacement; CP, chlamydia pneumoniae; FVII, factor 7; HR, hazard ratio on univariate analysis; MVR,
mitral valve replacement.
Figure 1. Kaplan Meier curve of event-free period for all throm-
boembolism by Risk Score (total number of risk factors) for
patients who underwent aortic, mitral or double valve replace-
ment. For each curve, freedom from TE at 4 years is indicated
by (F).
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involved in the pathogenesis of cancer-associated thrombo-
sis.14 In this study, 28% of patients with a cancer history had
a raised eosinophil count versus 13% of patients without
(P0.06), and a raised eosinophil count was also an inde-
pendent risk factor for TE.
Previous closed mitral valvotomy may be a direct risk
factor or may be a surrogate for rapid progression of
rheumatic disease in the mitral valve, leading to the necessity
for mitral valvotomy at an early stage. Closed mitral valvot-
omy involves ligation and amputation of the left atrial
appendage that can leave a rather corrugated irregular surface
within the left atrium but this usually becomes smoothed out
with time and does not appear irregular or thrombogenic at
subsequent operation for mitral valve replacement many
years later. Therefore, it is possible that whatever causes
rapid progression to mitral stenosis also makes the patient
more susceptible to thromboembolism. Some support for this
hypothesis comes from histologic examination of rheumatic
mitral valves that has shown that the progression of valve
thickening is because of repeated deposition of microthrom-
bus with subsequent organization.16
Postoperative infections in this study included 13 wound
infections, 2 pulmonary infections, 1 urinary-tract infection, 1
case of mediastinitis, and 1 intravenous line infection. Seven
patients with postoperative infections had 10 TE events (7
ischemic stroke in 5 patients and 3 TIA). On multivariate
analysis, considering time to first event in all patients, they
doubled the risk of subsequent TE. This suggests that stim-
ulation of an inflammatory response also activated the coag-
ulation system, as the two are known to be closely linked,17
and that this effect persisted following discharge from the
hospital. First events occurred within 6 months in 4 patients,
2 years in 2 patients, and within 6 years in 1 patient
suggesting that the effect, if present, was predominantly
related to the early postoperative months.
Some traditional risk factors for TE had little or no impact
on event rates in this study. Age in itself was not a risk factor,
suggesting that biological factors were more important than
mere chronological age. Similarly, nonsinus rhythm had little
impact probably because relatively few AVR patients and a
very high percentage of all MVR/DVR patients were in atrial
fibrillation (Table 3).
Among the laboratory variables identified as risk factors,
evidence of chronic infection with Chlamydia pneumoniae
emerged as the strongest predictor of future TE events with a
hazard ratio of 2.9. Chronic Chlamydial infection as a risk
factor for TE events after valve replacement is consistent with
similar data for stroke in the general population.18,19 Interest-
ingly Chlamydial infection was present in 5 out of 7 patients
who had both postoperative infection and subsequent TE
events and the hazard ratio for the combination of Chlamydial
infection and a postoperative infection was 8.3.
Of the other laboratory variables, most are known to be
prothrombotic when present in the circulation at raised
concentrations20 or, in the case of platelets, when platelet
volume is increased.21 However, none has previously been
shown to be a risk factor for TE events after valve replace-
ment. Factor VII usually falls to very low levels in patients on
warfarin. The discovery that absence of this response is a risk
factor is also a new finding and may have implications for the
monitoring of patients on warfarin. It is possible that warfarin
may have been stopped prior to acquisition of preoperative
venous blood in some patients, but despite this factor VII
Figure 2. Kaplan Meier curve of event-free period for major
thromboembolism (stroke or peripheral embolism) by Risk Score
(total number of risk factors) for patients who underwent aortic,
mitral or double valve replacement. The vertical axis goes from
65% to 100%. For each curve, freedom from TE at 4 years is
indicated by (F).
TABLE 6. Freedom from TE and Linearized Rates by Risk Score
Risk Score 0 1 2 3 4* 5* 6*
Sample size 31 90 105 76 42 13 3
Patient years 140.2 400.3 486.1 329.4 154.2 44.2 12.1
All Thromboembolic events:
Number of events 0 6 33 29 16 8 4
Freedom from event at 4 years (%) 100 95 81 74 65 30 0
Linearised Rate (%/yr) 0 1.5 6.8 8.8 10.4 18.1 33.1
Major Thromboembolic events:
Number of events 0 2 7 10 4 4 1
Freedom from event at 4 years (%) 100 98 96 91 89 67 67
Linearised Rate (%/yr) 0 0.5 1.4 3.0 2.6 9.0 8.3
*Estimates may be imprecise due to small sample sizes.
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remained elevated in patients with events [66(SD 37) v 55,25
P0.05] while preoperative INR measured at the same time
was not different between patients with and without events
[2.1 (SD 0.7) for both].
When patients with AVR and MVR or DVR were
assessed separately in terms of their risk factors for TE,
some differences emerged. Traditional ‘arterial’ risk fac-
tors such as diabetes and systemic hypertension were more
predictive after AVR, whereas previous mitral valvotomy
was only predictive after MVR/DVR. The effect of post-
operative infection as a risk factor was confined to AVR
patients. Of the laboratory variables, evidence of chronic
Chlamydial infection was a strong predictor of TE in both
AVR and MVR/DVR patients. A raised eosinophil count
was a strong predictor only in AVR patients, in keeping
with the effect of eosinophil activation on platelet activa-
tion,22 which is the dominant mechanism of thrombogen-
esis in the high shear stress conditions associated with
AVR.3 In contrast, the effect of inappropriately high levels
of factor VII while on warfarin, raised factor VIII, and
raised fibrinogen, occurred only or mainly in MVR/DVR
patients, in keeping with the dominant effect of the
coagulation system in determining the risk of TE in the
conditions of relative stasis in the left atrium often
associated with MVR.3 Increased platelet size was also
only a risk factor in association with MVR. Large platelets
are known to be more reactive21 and therefore, more
‘sticky’ and it is likely that this effect is more pronounced
in conditions of relative stasis, allowing platelets to adhere
more readily.
The finding that ‘arterial’ risk factors increase the risk of
TE in patients undergoing AVR is in keeping with previous
data we have published from a large prospective study based
on a single prosthesis (Medtronic Hall valve).23 However, in
that study, smoking also emerged as a risk factor, particularly
in patients who continued to smoke postoperatively, whereas
in this study smoking was not an independent risk factor. In
this smaller study, postoperative smoking was strongly dis-
couraged, but it is possible that the dominant effect of chronic
Chlamydial infection displaced pre-operative smoking per se
as a risk factor. This infection is known to be more prevalent
in smokers24 and in this study 41% of patients with chronic
Chlamydial infection were current or recent (5 years)
smokers whereas only 22% were nonsmokers (P0.001).
Recently it has been shown that atheroma in the carotid artery
develops or progresses among smokers only if they also have
evidence of chronic infection, including chronic Chlamydial
infection.25
Most of the blood tests found to be predictive of TE events
in this study are performed routinely in all hospitals at
minimal cost. The only test which is not routinely performed
and which is more expensive is that for IgA antibodies to
Chlamydia pneumoniae. However, because of its high pre-
dictive power, the cost seems justifiable.
The use of a scoring system based on pre-operative and
peri-operative variables should allow more accurate risk
stratification to inform discussions with patients about their
long-term risks after valve replacement. Knowledge of likely
long-term outcomes may also facilitate decisions about
choice of prosthesis (eg, mechanical versus biological), anti-
thrombotic management and the closeness of follow-up
required. However, the scoring system proposed here needs
to be tested further in other large prosthetic valve databases
before introduction to clinical practice.
The finding that patient variables make a huge difference
to the risk of TE events after valve replacement provides
further emphasis for the need to use caution in interpreting
unstratified TE rates after valve replacement reported in the
literature, particularly as a measure of prosthesis perfor-
mance. Common sense dictates that cerebrovascular events,
the most common manifestation of ‘thromboembolism’, are
likely to be multifactoral in their etiology and related not only
to the presence of a prosthetic valve and antithrombotic
management but also to factors associated with atherosclero-
sis, inherent diverse mechanisms of hypercoagulability and
pre-existing intracardiac flow conditions.
The findings of this study also have implications for the
future management of patients with prosthetic valves in terms
of reducing their risk of thromboembolism. In the case of risk
factors that are amenable to modification, further prospective
studies are required to test the hypothesis that amelioration or
abolition of these factors will reduce the incidence of
thromboembolism.
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